With the development of immunotherapies such as cancer vaccine, immune checkpoint inhibitors, oncolytic virus, and chimeric antigen receptor T cell (CAR-T) therapy (64), a combination of NRF2-targeting agonists and immunotherapies may provide multiple feasible approaches to new BC treatment strategies. The gene discussed is NFE2L2; the disease is cancer.